Comparison · NCT05483933-9487f47a
Pegylated Liposomal Doxorubicin + SL-172154 vs Mirvetixumab + SL-172154: Evaluate Safety and Tolerability of SL-172154 When Administered With PLD or Mirvetixumab
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pegylated Liposomal Doxorubicin + SL-172154 vs Mirvetixumab + SL-172154: Evaluate Safety and Tolerability of SL-172154 When Administered With PLD or Mirvetixumab. Trial comparisons, record NCT05483933-9487f47a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05483933-9487f47a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.952 | 0.773 | 0.992 | wilson | |
| Risk in group 2 | 1 | 0.944 | 1 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0476 | -0.227 | 0.0206 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.952 | 0.866 | 1.05 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on Pegylated Liposomal Doxorubicin + SL-172154 than on Mirvetixumab + SL-172154 | 21 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pegylated Liposomal Doxorubicin + SL-172154 | 3.0 mg/kg SL-172154 on Days 8 and15 of every 28-day cycle plus pegylated liposomal doxorubicin (PLD) 40 mg/m2 on Day 1 of every 28-day cycle | 20 | 21 | OG000 |
| Group 2 | Mirvetixumab + SL-172154 | 3.0 mg/kg SL-172154 on Days 8 and15 of every 21-day cycle plus mirvetuximab (MIRV) 6.0 mg/kg on Day 1 of every 21-day cycle | 65 | 65 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Evaluate Safety and Tolerability of SL-172154 When Administered With PLD or Mirvetixumab
- Description
- Number of participants with treatment emergent adverse events from dose escalation and expansion cohorts
- Time frame
- From Day 1 to 30 days after last dose of SL-172154, PLD or Mirvetixumab, an average of approximately 6 months
- Population
- Subjects who received at least one dose of SL-172154, PLD or Mirvetixumab
Source ClinicalTrials.gov
Trial
- Title
- Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
- NCT number
- NCT05483933
- Phases
- PHASE1
- Conditions
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
- Interventions
- Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154
- Lead sponsor
- Shattuck Labs, Inc.
- Results first posted
- 2025-12-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05483933?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05483933-9487f47a